|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
CA2124967C
(en)
|
1991-12-17 |
2008-04-08 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5625825A
(en)
|
1993-10-21 |
1997-04-29 |
Lsi Logic Corporation |
Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
|
|
WO1996031598A1
(en)
|
1995-04-06 |
1996-10-10 |
Regeneron Pharmaceuticals, Inc. |
Tie-2 ligands, methods of making and uses thereof
|
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
|
JP3957765B2
(ja)
|
1997-04-07 |
2007-08-15 |
ジェネンテク・インコーポレイテッド |
抗ｖｅｇｆ抗体
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US6316109B1
(en)
|
2000-09-21 |
2001-11-13 |
Ppg Industries Ohio, Inc. |
Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers
|
|
CN1318093C
(zh)
|
2001-09-28 |
2007-05-30 |
参天制药株式会社 |
含与聚乙二醇结合的药物的眼组织注射剂
|
|
US20030158083A1
(en)
|
2002-02-08 |
2003-08-21 |
The Procter & Gamble Company |
Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
|
|
US20030215899A1
(en)
|
2002-02-13 |
2003-11-20 |
Ceptyr, Inc. |
Reversible oxidation of protein tyrosine phosphatases
|
|
US7226755B1
(en)
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
|
US7507568B2
(en)
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20050059639A1
(en)
|
2003-09-11 |
2005-03-17 |
Wei Edward T. |
Ophthalmic compositions and method for treating eye discomfort and pain
|
|
LT2653465T
(lt)
|
2004-03-15 |
2016-09-12 |
Janssen Pharmaceutica Nv |
Opioidinio receptoriaus moduliatoriai
|
|
CA2599606A1
(en)
|
2005-02-23 |
2006-08-31 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
|
US20120237442A1
(en)
|
2005-04-06 |
2012-09-20 |
Ibc Pharmaceuticals, Inc. |
Design and Construction of Novel Multivalent Antibodies
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
WO2007033216A2
(en)
|
2005-09-12 |
2007-03-22 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
JP2009510102A
(ja)
|
2005-09-29 |
2009-03-12 |
ヴァイラル ロジック システムズ テクノロジー コーポレーション |
免疫調節組成物およびその使用
|
|
CA2633211A1
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
|
EP1981520A2
(en)
|
2006-01-30 |
2008-10-22 |
(OSI) Eyetech, Inc. |
Combination therapy for the treatment of neovascular disorders
|
|
AU2007237096C1
(en)
|
2006-04-07 |
2012-12-13 |
EyePoint, Inc. |
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
|
|
US7608261B2
(en)
|
2006-06-16 |
2009-10-27 |
Regeneron Pharmacuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US10259860B2
(en)
*
|
2007-02-27 |
2019-04-16 |
Aprogen Inc. |
Fusion proteins binding to VEGF and angiopoietin
|
|
US20100256147A1
(en)
|
2007-04-13 |
2010-10-07 |
Hangauer Jr David G |
Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders
|
|
EP2170402B1
(en)
|
2007-06-26 |
2015-03-25 |
Children's Medical Center Corporation |
Metap-2 inhibitor polymersomes for therapeutic administration
|
|
US20100221252A1
(en)
|
2007-06-29 |
2010-09-02 |
Schering Corporation |
Mdl-1 uses
|
|
RU2010120674A
(ru)
|
2007-10-22 |
2011-11-27 |
Шеринг Корпорейшн (US) |
Полностью человеческие анти-vegf-антитела и способы их применения
|
|
WO2009105774A2
(en)
|
2008-02-21 |
2009-08-27 |
Sequoia Pharmaceuticals, Inc. |
Amino acid inhibitors of cytochrome p450
|
|
US8293714B2
(en)
|
2008-05-05 |
2012-10-23 |
Covx Technology Ireland, Ltd. |
Anti-angiogenic compounds
|
|
LT3216803T
(lt)
|
2008-06-25 |
2020-06-10 |
Novartis Ag |
Stabilūs ir tirpūs antikūnai, slopinantys vegf
|
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
EP3785735A1
(en)
|
2008-11-03 |
2021-03-03 |
Molecular Partners AG |
Binding proteins inhibiting the vegf-a receptor interaction
|
|
SG10201702247SA
(en)
|
2009-01-12 |
2017-04-27 |
Aerpio Therapeutics Inc |
Methods for treating vascular leak syndrome
|
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
|
MY160399A
(en)
|
2009-07-06 |
2017-03-15 |
Aerpio Therapeutics Inc |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
EP3698794A1
(en)
|
2009-11-06 |
2020-08-26 |
Aerpio Therapeutics, Inc. |
Compositions and methods for treating colitis
|
|
CA2782333C
(en)
|
2009-12-02 |
2019-06-04 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
CN102711756A
(zh)
|
2010-01-14 |
2012-10-03 |
株式会社三和化学研究所 |
用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
|
|
CA3083324A1
(en)
|
2010-03-05 |
2011-09-09 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
US20180092883A1
(en)
|
2010-10-07 |
2018-04-05 |
Aerpio Therapeutics, Inc. |
Phosphatase inhibitors for treating ocular diseases
|
|
US20120129847A1
(en)
|
2010-10-07 |
2012-05-24 |
Kevin Gene Peters |
Compositions and methods for treating ocular edema, neovascularization and related diseases
|
|
KR20260004598A
(ko)
|
2011-01-13 |
2026-01-08 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
|
AU2012323856B2
(en)
|
2011-10-13 |
2017-05-25 |
EyePoint, Inc. |
Methods for treating Vascular Leak Syndrome and cancer
|
|
EP3501536B1
(en)
|
2011-10-13 |
2025-12-24 |
EyePoint Pharmaceuticals, Inc. |
Treatment of ocular disease
|
|
HUE046134T2
(hu)
|
2012-05-07 |
2020-02-28 |
Allergan Inc |
Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
|
|
LT3495387T
(lt)
|
2012-07-13 |
2021-11-25 |
Roche Glycart Ag |
Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
|
|
EP2890389A1
(en)
|
2012-08-28 |
2015-07-08 |
Novartis AG |
Use of a vegf antagonist in treating ocular vascular proliferative diseases
|
|
US20150050277A1
(en)
|
2013-03-15 |
2015-02-19 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
|
AU2014233363B2
(en)
|
2013-03-15 |
2017-06-29 |
EyePoint, Inc. |
Compositions, formulations and methods for treating ocular diseases
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
WO2015058048A1
(en)
|
2013-10-18 |
2015-04-23 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
|
|
CA2927012A1
(en)
|
2013-11-05 |
2015-05-14 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
|
SG11201605580RA
(en)
|
2014-01-10 |
2016-10-28 |
Anaptysbio Inc |
Antibodies directed against interleukin-33 (il-33)
|
|
CN105026433B
(zh)
*
|
2014-01-24 |
2018-10-19 |
上海恒瑞医药有限公司 |
VEGF与PDGFRβ双特异性融合蛋白及其用途
|
|
US9719135B2
(en)
|
2014-07-03 |
2017-08-01 |
Mannin Research Inc. |
Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
|
|
WO2016022813A1
(en)
|
2014-08-07 |
2016-02-11 |
Aerpio Therapeutics, Inc. |
Combination of immunotherapies with activators of tie-2
|
|
WO2016044436A2
(en)
|
2014-09-16 |
2016-03-24 |
Ovascience, Inc. |
Anti-vasa antibodies, and methods of production and use thereof
|
|
WO2016049183A1
(en)
|
2014-09-24 |
2016-03-31 |
Aerpio Therapeutics, Inc. |
Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
|
|
TWI738632B
(zh)
*
|
2014-11-07 |
2021-09-11 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
PT3230316T
(pt)
|
2014-12-11 |
2022-02-24 |
Bayer Healthcare Llc |
Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
|
|
WO2016115092A1
(en)
|
2015-01-12 |
2016-07-21 |
La Jolla Institute For Allergy And Immunology |
Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
|
|
AR103477A1
(es)
|
2015-01-28 |
2017-05-10 |
Lilly Co Eli |
Compuestos de vegfa / ang2
|
|
AU2016240220B2
(en)
|
2015-04-02 |
2019-11-21 |
Molecular Partners Ag |
Designed ankyrin repeat domains with binding specificity for serum albumin
|
|
WO2017035430A2
(en)
|
2015-08-27 |
2017-03-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-alk antibodies and methods for use thereof
|
|
RU2763916C2
(ru)
|
2015-09-23 |
2022-01-11 |
Дженентек, Инк. |
Оптимизированные варианты анти-vegf антител
|
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
AU2017299581B2
(en)
|
2016-07-20 |
2024-05-23 |
EyePoint, Inc. |
Humanized monoclonal antibodies that target ve-ptp (hptp-β)
|
|
MX2019003895A
(es)
|
2016-10-04 |
2019-10-07 |
Asclepix Therapeutics Inc |
Compuestos y metodos para activar la señalizacion tie2.
|
|
IT201600120314A1
(it)
|
2016-11-28 |
2018-05-28 |
Nuovo Pignone Tecnologie Srl |
Turbo-compressore e metodo di funzionamento di un turbo-compressore
|
|
US10426817B2
(en)
|
2017-01-24 |
2019-10-01 |
Macregen, Inc. |
Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
|
|
JP2020521759A
(ja)
|
2017-05-26 |
2020-07-27 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
CN107602702A
(zh)
|
2017-09-22 |
2018-01-19 |
生标（上海）医疗器械科技有限公司 |
一种同时靶向人p185和血管内皮生长因子的抗体及其应用
|
|
EP4122486A1
(en)
|
2017-11-30 |
2023-01-25 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist to treat diabetic retinopathy
|
|
WO2019168947A1
(en)
|
2018-02-28 |
2019-09-06 |
Ap Biosciences, Inc. |
Bifunctional proteins combining checkpoint blockade for targeted therapy
|
|
KR20200131839A
(ko)
|
2018-03-16 |
2020-11-24 |
노파르티스 아게 |
안질환의 치료 방법
|
|
US10276202B1
(en)
|
2018-04-23 |
2019-04-30 |
Western Digital Technologies, Inc. |
Heat-assisted magnetic recording (HAMR) medium with rhodium or rhodium-based alloy heat-sink layer
|
|
US11103552B2
(en)
|
2018-05-10 |
2021-08-31 |
Regeneron Pharmaceuticals, Inc. |
High concentration VEGF receptor fusion protein containing formulations
|
|
CA3100349A1
(en)
|
2018-05-17 |
2019-11-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor inhibition by phosphatase recruitment
|
|
US11066476B2
(en)
|
2018-09-14 |
2021-07-20 |
Shanghai tongji hospital |
Asymmetric bispecific antibody
|
|
CN120058958A
(zh)
|
2018-09-24 |
2025-05-30 |
视点制药公司 |
靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
|